TG THERAPEUTICS INC (NASDAQ:TGTX) has been brought to our attention through a screening process that combines two distinct, yet complementary, approaches. The first is a high-growth momentum filter, which seeks out companies with accelerating earnings and revenue. The second is the Mark Minervini Trend Template, a set of strict technical criteria designed to identify stocks that are in a strong, sustained uptrend. By combining these two methods, we aim to find stocks that not only have solid fundamental momentum but are also confirming that strength through clear positive price action. This creates a potential recipe for stocks that are not just good companies, but also leading current market performers.
Technical Alignment with the Minervini Trend Template
A central component of the Minervini strategy is the Trend Template, a strict checklist to ensure a stock is in a "Stage 2" uptrend. TGTX passes this test with flying colors. The current price of $53.52 is well above its 50-day ($42.89), 150-day ($34.80), and 200-day ($34.54) simple moving averages. Furthermore, all these averages are rising, confirming a strong long-term bullish structure. The alignment, where the 50-day sits comfortably above the longer-term averages, is a textbook sign of accelerating momentum.
The stock also performs well on Minervini's price and relative strength criteria. At $53.52, the stock is more than 100% above its 52-week low of $25.28, far exceeding the 30% minimum threshold. It is also trading within 7% of its 52-week high of $57.38, a sign of exceptional relative strength. This is further confirmed by its ChartMill Relative Strength (CRS) score of 91.58, meaning it has outperformed over 91% of all stocks in the market. In the Minervini framework, such a high relative strength rank is a prerequisite, as it points to institutional accumulation.
Fundamental Strength for High Growth Investors
The high growth momentum screen looks for a different, but equally important, set of signals. While the Minervini template confirms the trend, the fundamentals explain why the trend exists. The data for TGTX shows a company in a clear earnings acceleration phase.
-
EPS Growth: The most recent quarter (Q2Q) showed EPS growth of a remarkable 500% compared to the same quarter last year. This is a massive acceleration from the previous quarter which showed a decline of -6.7%, breaking a pattern of very high growth. The overall TTM (trailing twelve months) EPS growth is an impressive 170.8%.
-
Revenue Growth: The top line is also accelerating. Quarterly revenue was up 69.6% year-over-year, following a 78% and 92.8% growth in the prior two quarters, respectively. This consistent, high double-digit growth is a key characteristic of a high-growth momentum stock.
-
Profitability: The company is now clearly profitable. While the profit margin in the most recent quarter was 9.65%, the full-year (FY) profit margin stands at an impressive 72.6%, a massive jump from 7.1% the previous year. This signals a business that is scaling its operations effectively and generating significant bottom-line returns.
-
Earnings Revisions: While the EPS estimate revisions for the next year have been slightly negative (-13% over 3 months), the revenue estimate revisions are positive (+4.3% over 3 months), suggesting analysts are adjusting their models but still see a strong top-line trajectory.
The interaction between the technical and fundamental is critical here. The accelerating earnings and revenue (from the high growth screen) provide the catalyst. The perfect alignment of moving averages and high relative strength (from the Minervini template) confirms that the market is recognizing this strength and is aggressively bidding up the price.
Current Technical Picture and Setup Quality
Our detailed technical analysis report supports the overall bullish narrative. The stock currently holds an excellent technical rating of 9 out of 10, indicating exceptionally strong technical health. The short-term and long-term trends are both clearly positive. The stock is not only outperforming the market, outperforming 91% of all stocks, but is also a leader within its own industry, outperforming 73% of stocks in the Biotechnology sector. Trading near its 52-week high, TGTX is demonstrating clear leadership.
However, the setup rating is currently a 5 out of 10. This is a critical nuance. A high technical rating means the stock is a great company in a strong uptrend. A lower setup rating means that, at this precise moment, the price action has been a bit too volatile to offer a clean, low-risk entry point. The stock has moved from $38 to $57 in a relatively short period, making a consolidation or a pullback likely before its next leg higher. Minervini traders would typically wait for a volatility contraction pattern (VCP) — a period of tight, sideways price action on declining volume — to form before initiating a new position.
For a more detailed breakdown of these ratings and the specific support levels, you can view the full technical analysis report here.
Conclusion & Next Steps
TG Therapeutics (TGTX) presents a persuasive case of a stock firing on all fronts. It passes the strict technical criteria of the Minervini Trend Template while also displaying the accelerating earnings and revenue growth prized by high-growth momentum investors. The primary caveat is the current setup quality, which suggests that patience is required. A disciplined trader would add this stock to a watchlist and wait for a proper pullback or consolidation to form before committing capital.
Discover More Potential Leaders
This analysis was generated from a screen that combines Mark Minervini's technical criteria with a high-growth momentum filter. To find the most recent stocks that are passing this powerful combination of tests, you can run the screen yourself and start building your own watchlist.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Please do your own research or consult with a financial professional before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
TG THERAPEUTICS INC (NASDAQ:TGTX): High-Growth Momentum Meets Minervini Trend Template Technical Strength
TG THERAPEUTICS INC (NASDAQ:TGTX) has been brought to our attention through a screening process that combines two distinct, yet complementary, approaches. The first is a high-growth momentum filter, which seeks out companies with accelerating earnings and revenue. The second is the Mark Minervini Trend Template, a set of strict technical criteria designed to identify stocks that are in a strong, sustained uptrend. By combining these two methods, we aim to find stocks that not only have solid fundamental momentum but are also confirming that strength through clear positive price action. This creates a potential recipe for stocks that are not just good companies, but also leading current market performers.
Technical Alignment with the Minervini Trend Template
A central component of the Minervini strategy is the Trend Template, a strict checklist to ensure a stock is in a "Stage 2" uptrend. TGTX passes this test with flying colors. The current price of $53.52 is well above its 50-day ($42.89), 150-day ($34.80), and 200-day ($34.54) simple moving averages. Furthermore, all these averages are rising, confirming a strong long-term bullish structure. The alignment, where the 50-day sits comfortably above the longer-term averages, is a textbook sign of accelerating momentum.
The stock also performs well on Minervini's price and relative strength criteria. At $53.52, the stock is more than 100% above its 52-week low of $25.28, far exceeding the 30% minimum threshold. It is also trading within 7% of its 52-week high of $57.38, a sign of exceptional relative strength. This is further confirmed by its ChartMill Relative Strength (CRS) score of 91.58, meaning it has outperformed over 91% of all stocks in the market. In the Minervini framework, such a high relative strength rank is a prerequisite, as it points to institutional accumulation.
Fundamental Strength for High Growth Investors
The high growth momentum screen looks for a different, but equally important, set of signals. While the Minervini template confirms the trend, the fundamentals explain why the trend exists. The data for TGTX shows a company in a clear earnings acceleration phase.
EPS Growth: The most recent quarter (Q2Q) showed EPS growth of a remarkable 500% compared to the same quarter last year. This is a massive acceleration from the previous quarter which showed a decline of -6.7%, breaking a pattern of very high growth. The overall TTM (trailing twelve months) EPS growth is an impressive 170.8%.
Revenue Growth: The top line is also accelerating. Quarterly revenue was up 69.6% year-over-year, following a 78% and 92.8% growth in the prior two quarters, respectively. This consistent, high double-digit growth is a key characteristic of a high-growth momentum stock.
Profitability: The company is now clearly profitable. While the profit margin in the most recent quarter was 9.65%, the full-year (FY) profit margin stands at an impressive 72.6%, a massive jump from 7.1% the previous year. This signals a business that is scaling its operations effectively and generating significant bottom-line returns.
Earnings Revisions: While the EPS estimate revisions for the next year have been slightly negative (-13% over 3 months), the revenue estimate revisions are positive (+4.3% over 3 months), suggesting analysts are adjusting their models but still see a strong top-line trajectory.
The interaction between the technical and fundamental is critical here. The accelerating earnings and revenue (from the high growth screen) provide the catalyst. The perfect alignment of moving averages and high relative strength (from the Minervini template) confirms that the market is recognizing this strength and is aggressively bidding up the price.
Current Technical Picture and Setup Quality
Our detailed technical analysis report supports the overall bullish narrative. The stock currently holds an excellent technical rating of 9 out of 10, indicating exceptionally strong technical health. The short-term and long-term trends are both clearly positive. The stock is not only outperforming the market, outperforming 91% of all stocks, but is also a leader within its own industry, outperforming 73% of stocks in the Biotechnology sector. Trading near its 52-week high, TGTX is demonstrating clear leadership.
However, the setup rating is currently a 5 out of 10. This is a critical nuance. A high technical rating means the stock is a great company in a strong uptrend. A lower setup rating means that, at this precise moment, the price action has been a bit too volatile to offer a clean, low-risk entry point. The stock has moved from $38 to $57 in a relatively short period, making a consolidation or a pullback likely before its next leg higher. Minervini traders would typically wait for a volatility contraction pattern (VCP) — a period of tight, sideways price action on declining volume — to form before initiating a new position.
For a more detailed breakdown of these ratings and the specific support levels, you can view the full technical analysis report here.
Conclusion & Next Steps
TG Therapeutics (TGTX) presents a persuasive case of a stock firing on all fronts. It passes the strict technical criteria of the Minervini Trend Template while also displaying the accelerating earnings and revenue growth prized by high-growth momentum investors. The primary caveat is the current setup quality, which suggests that patience is required. A disciplined trader would add this stock to a watchlist and wait for a proper pullback or consolidation to form before committing capital.
Discover More Potential Leaders
This analysis was generated from a screen that combines Mark Minervini's technical criteria with a high-growth momentum filter. To find the most recent stocks that are passing this powerful combination of tests, you can run the screen yourself and start building your own watchlist.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Please do your own research or consult with a financial professional before making any investment decisions.
Read full article here »